9,365 Shares in Boston Scientific Corporation (NYSE:BSX) Acquired by Little House Capital LLC

Little House Capital LLC purchased a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 9,365 shares of the medical equipment provider's stock, valued at approximately $945,000.

Several other institutional investors and hedge funds also recently made changes to their positions in BSX. Colonial Trust Co SC boosted its holdings in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Investment Management Corp VA ADV acquired a new position in Boston Scientific during the fourth quarter worth $25,000. Sunbeam Capital Management LLC acquired a new position in Boston Scientific during the fourth quarter worth $26,000. Ameriflex Group Inc. acquired a new position in Boston Scientific during the fourth quarter worth $31,000. Finally, Fairway Wealth LLC acquired a new position in Boston Scientific during the fourth quarter worth $36,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total value of $5,799,551.36. Following the transaction, the executive vice president now directly owns 178,342 shares of the company's stock, valued at $18,347,824.96. This trade represents a 24.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president now directly owns 18,705 shares in the company, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Performance

Shares of BSX traded up $2.25 during trading hours on Friday, hitting $106.83. The company had a trading volume of 15,636,958 shares, compared to its average volume of 6,623,509. Boston Scientific Corporation has a 12 month low of $71.88 and a 12 month high of $107.17. The firm has a market cap of $158.05 billion, a price-to-earnings ratio of 39.46, a PEG ratio of 2.75 and a beta of 0.68. The business has a fifty day moving average of $102.74 and a 200-day moving average of $99.62. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The business had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period last year, the firm earned $0.56 earnings per share. Boston Scientific's revenue for the quarter was up 20.9% compared to the same quarter last year. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

BSX has been the subject of several recent research reports. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Royal Bank Of Canada increased their price target on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Citigroup reiterated a "buy" rating and issued a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Finally, Morgan Stanley increased their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Twenty-two equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $116.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.